Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370881 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9HPGD | |
| SCHEMBL19582680 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9HPGD | |
| SCHEMBL2409552 | 0.93 | CA12 (0.53) | CA12CA1CA2CA9HPGD | |
| SCHEMBL1666565 | 0.93 | CA12 (0.53) | CA12CA1CA2CA9HPGD | |
| SCHEMBL200488 | 0.93 | CA12 (0.53) | CA12CA1CA2CA9HPGD | |
| Ammonia Solution, Strong SCHEMBL7354973 | 0.91 | CA12 (0.52) | CA12CA1CA2CA9HPGD | |
| Ammonia Solution, Strong SCHEMBL7354978 | 0.91 | CA12 (0.52) | CA12CA1CA2CA9HPGD | |
| Ammonia Solution, Strong SCHEMBL7360612 | 0.91 | CA12 (0.52) | CA12CA1CA2CA9HPGD | |
| Alcohol SCHEMBL7359179 | 0.84 | CA12 (0.46) | CA12CA1CA2CA9DPP4 | |
| Butane SCHEMBL28217400 | 0.84 | CA12 (0.46) | CA12CA1CA2CA9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | CA12 2965/4885CA1 1934/4885CA2 4637/4885 |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | CA12 2051/4885CA1 3193/4885CA2 2566/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | CA12 2965/4885CA1 1934/4885CA2 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.